Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation

Leukemia & Lymphoma
Jose Leis, David L Porter

Abstract

Allogeneic stem cell transplantation (SCT) may cure many patients with hematologic malignancies due to both the intensive conditioning therapy, and in many patients, the potent graft-vs-leukemia (GVL) effect of the donor graft. The GVL effect is mediated in large part by mature T-cells contained in the donor graft and has been defined in detail in animal models of transplantation. The GVL activity has been observed in the clinical setting after SCT from both matched siblings and unrelated donors. The best demonstration and most direct evidence of GVL activity in humans come from the use of donor leukocyte infusions (DLI). For patients who relapse with chronic myelogenous leukemia after matched sibling SCT, infusions of leukocytes collected from the original transplant donor will re-establish complete and durable remission in 60-80% of patients. DLI is less effective for more advanced phases of CML and for patients who relapse with diseases other than CML. DLI after matched sibling SCT is complicated primarily by graft-vs-host disease (GVHD), marrow aplasia, and unfortunately, relapse in some cases. There has been little information regarding the use of unrelated DLI (UDLI). Available data now shows that despite initial concerns...Continue Reading

References

Jun 18, 1981·The New England Journal of Medicine·P L WeidenUNKNOWN Seattle Marrow Transplant Team
Apr 15, 1994·Annals of Internal Medicine·R P GaleM M Bortin
Jan 13, 1994·The New England Journal of Medicine·D L PorterJ H Antin
Feb 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P RadichJ A Hansen
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R H CollinsJ Nemunaitis
Jul 25, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·M E FlowersP Martin
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M LokhorstL F Verdonck
Oct 6, 2000·Bone Marrow Transplantation·R H CollinsP Parker
Jan 10, 2001·Bone Marrow Transplantation·M SalamaR H Collins
Dec 1, 2001·Expert Opinion on Biological Therapy·V Bhatia, D L Porter

❮ Previous
Next ❯

Citations

Jan 14, 2003·Hematological Oncology
Aug 12, 2006·Current Oncology Reports·Esperanza B Papadopoulos, Ann A Jakubowski
Dec 20, 2003·Blood Reviews·Mark R Litzow
Jul 27, 2011·Expert Review of Clinical Immunology·Aleksandra Petrovic, Gregory Hale
Jan 18, 2006·Seminars in Hematology·David Porter, John E Levine
Jan 2, 2009·Journal of Hematology & Oncology·Xiao-jun Huang
Apr 24, 2007·Best Practice & Research. Clinical Haematology·F Dazzi, C Fozza
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joshua BrodyRonald Levy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.